3B Blackbio DX Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹22Cr
- −4.3% YoY
- −12% QoQ
- Net profit
- ₹8Cr
- −11.1% YoY
- −38.5% QoQ
- Margin
- 35%
- −8 pp YoY
- −24 pp QoQ
Guidance rank: #34 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
3B Blackbio DX Ltd Q4 FY25 key numbers
- Revenue
- Consolidated sales in Q4 2024-25: INR 1,947.96 Lakh vs INR 1,906.48 Lakh in Q4 2023-24 (including TRUPCR Europe Limited sales of INR 187.18 Lakh).
As stated in 3B Blackbio DX Ltd's Q4 FY25 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on 3B Blackbio DX Ltd's Q4 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q4 FY 2024-25 revenue: INR 2,249.51 Lakh; Q4 FY 2023-24 revenue: INR 2,299.80 Lakh (slight YoY decrease). EBITDA for Q4 2024-25: INR 1,253.91 Lakh - Year-on-year change: Decrease from INR 1,372.90 Lakh (Q4 2023-24) - Profit After Tax (PAT) for Q4 2024-25: INR 803.55 Lakh - Year-on-year change: Decrease from INR 879.03 Lakh (Q4 2023-24) - Revenue from Operations for Q4 2024-25: INR 2,249.51 Lakh - Year-on-year change: Slight decrease from INR 2,299.80 Lakh (Q4 2023-24)
From 3B Blackbio DX Ltd's Q4 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q4 FY 2024-25 revenue: INR 2,249.51 Lakh; Q4 FY 2023-24 revenue: INR 2,299.80 Lakh (slight YoY decrease).
- Consolidated sales in Q4 2024-25: INR 1,947.96 Lakh vs INR 1,906.48 Lakh in Q4 2023-24 (including TRUPCR Europe Limited sales of INR 187.18 Lakh).
- Export sales Q4 2024-25: INR 410.40 Lakh vs INR 290.15 Lakh in Q4 2023-24 (substantial increase).
- UK subsidiary (TRUPCR Europe Limited) revenue FY 2024-25: GBP 1,287,580, a 94% increase over FY 2023-24 GBP 664,059. Projected 20-25% growth in FY 2025-26.
2 more points from 3B Blackbio DX Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
3B Blackbio DX Ltd — Quarterly revenue & net profit
3B Blackbio DX Ltd Q4 FY25 results — key figures
| ₹ Cr | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 22 | 23 | -4.3% | 25 | -12% |
| Operating profit (EBITDA) | 8 | 10 | -20% | 15 | -46.7% |
| Operating margin | 35% | 43% | -8 pp | 59% | -24 pp |
| Profit before tax | 13 | 14 | -7.1% | 18 | -27.8% |
| Net profit (PAT) | 8 | 9 | -11.1% | 13 | -38.5% |
| EPS (₹) | 9.79 | 10.33 | -5.2% | 15.61 | -37.3% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What 3B Blackbio's management said in earlier quarters
Others in Healthcare Services this season
- Apollo Hospitals (Q4 FY25)
. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Shalby (Q4 FY25)
Implant business is in high-growth mode: 4x growth in Indonesia, 35-40% growth in U.S., and 2.5x growth in India reported last year. Key concall takeaways from…
- Narayana Hrudaya (Q4 FY25)
Capex is split between regular maintenance/replacement (~INR 300 crores) and new greenfield/brownfield capacity (~INR 450 crores) with some variability based…
- Healthcare Global Enterprises (Q4 FY25)
FY '25 revenue grew 16% to INR 2,223 crores; Q4 revenue rose 18% YoY to INR 585 crores. Key concall takeaways from Healthcare Global Enterprises Ltd's Q4 FY25…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
3B Blackbio DX Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were 3B Blackbio DX Ltd Q4 FY25 results?
Q4 FY 2024-25 revenue: INR 2,249.51 Lakh; Q4 FY 2023-24 revenue: INR 2,299.80 Lakh (slight YoY decrease). EBITDA for Q4 2024-25: INR 1,253.91 Lakh - Year-on-year change: Decrease from INR 1,372.90 Lakh (Q4 2023-24) - Profit After Tax (PAT) for Q4 2024-25: INR 803.55 Lakh - Year-on-year change: Decrease from INR 879.03 Lakh (Q4 2023-24) - Revenue from Operations for Q4 2024-25: INR 2,249.51 Lakh - Year-on-year change: Slight decrease from INR 2,299.80 Lakh (Q4 2023-24)
What is 3B Blackbio DX Ltd share price analysis?
3B Blackbio DX Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹1,132 Cr. Investors should review the full earnings analysis for detailed insights.
Is 3B Blackbio DX Ltd planning capital expenditure?
The company is continuously investing in building additional manufacturing and R&D facilities/capacities to support existing business verticals (Page 41). - New products are being designed and launched to meet increasing market needs and maintain growth momentum (Page 41). - A joint venture in Manchester, UK, may receive funding deployment depending on need (Page 41). - Expansion focus appears on enhancing current manufacturing/R&D capacities rather than new plants (Page 41).
Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
